The avidin market size is projected to be USD 238.80 million in 2025, USD 252.17 million in 2026, and reach USD 343.20 million by 2031, growing at a CAGR of 6.36% from 2026 to 2031. This report is Segmented by Type (Native, Recombinant, Streptavidin), Grade (Research, Pharmaceutical, Diagnostic), Application (Diagnostics, Therapeutics, R&D, Biotech), Form (Liquid, Powdered, Lyophilized), End User (Biotech & Pharma, Research Institutions, Diagnostic Labs, Others), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Engineered variants such as HookDin are positioned as direct performance alternatives because the product page states that the format delivers 200% greater signal intensity than conventional options while reducing background noise by 75% through a near neutral surface charge and the absence of oligomannosidic glycans.
Recombinant avidin is projected to grow at 7.53% CAGR from 2026 to 2031, the fastest rate among type segments in the avidin industry, because engineering flexibility and supply independence are becoming more valuable in high-sensitivity use cases. HookDin illustrates the appeal of this direction, since the company states that the format provides 3 times the biotin binding capacity of monomeric streptavidin on nitrocellulose membranes and cuts background noise by 75%.
Research grade avidin accounted for 60.34% of the avidin market in 2025, which reflected the large volume consumed in academic laboratories and industrial research workflows where cost and availability remained more important than very tight release specifications. That segment continued to benefit from routine use in protein purification, ELISA development, cell labeling, and general molecular biology work.
Diagnostic grade avidin is expected to expand at 7.82% CAGR between 2026 and 2031, the fastest pace among grade segments in the avidin market, because more commercial diagnostic demand is moving under formal quality expectations. A key part of that growth comes from a reclassification pattern in which some Asia Pacific manufacturers that have used research grade material for kit production will face stronger compliance pressure as local frameworks move closer to ISO 13485 aligned standards.
Europe remained the second largest regional market in the avidin market, with Germany, the United Kingdom, and France acting as the main contributors across research, diagnostic, and pharmaceutical grades. Germany benefits from strong pharmaceutical and diagnostic manufacturing, the United Kingdom contributes through a well developed biotechnology base, and France adds stable academic demand.
Asia Pacific is projected to expand at 7.89% CAGR from 2026 to 2031, the fastest regional pace in the avidin market size, because the region combines China’s large IVD manufacturing base, India’s healthcare buildout, Japan’s advanced research environment, and South Korea’s mature diagnostics ecosystem. China remains the largest regional contributor because high volume ELISA and lateral flow production requires steady procurement of avidin related inputs across multiple kit categories.
Global Avidin Market Trends and Insights
Rising Demand for High Specificity Biotin Binding Reagents in Diagnostic Assays
The avidin market is seeing stronger pull from ELISA, lateral flow, and multi analyte immunoassay systems used in oncology, infectious disease, and metabolic screening, where signal consistency directly affects test performance. Buyers are placing greater value on precisely characterized biotin binding reagents because next generation digital immunoassays are moving toward femtomolar detection and leave less tolerance for background variation. A 2026 study in Microsystems & Nanoengineering demonstrated a fully automated digital immunoassay on a microfluidic cartridge that integrated pre freeze dried streptavidin phycoerythrin and biotin conjugated detection antibodies, which shows how tightly modern compact assays still depend on this chemistry.Growth in Recombinant and Low Nonspecific Binding Avidin Formats
The avidin market is moving toward recombinant formats because clinical diagnostics and cell-based assays place a higher premium on low nonspecific background than on the cost advantage of native egg white avidin. Supply security is also becoming part of the buying decision, since native avidin depends on egg white extraction and remains exposed to agricultural disruptions tied to highly pathogenic avian influenza events that have remained relevant since 2024.Engineered variants such as HookDin are positioned as direct performance alternatives because the product page states that the format delivers 200% greater signal intensity than conventional options while reducing background noise by 75% through a near neutral surface charge and the absence of oligomannosidic glycans.
Substitution by Streptavidin, NeutrAvidin, and Alternative Binding Chemistries
The avidin market faces a structural substitution risk because native avidin carries a much higher isoelectric point than streptavidin, which increases nonspecific binding to negatively charged surfaces and cell membranes in many clinical grade applications. That property has made streptavidin the default choice in many immunoassay and flow cytometry protocols, and published workflows then reinforce the preference as newer laboratories adopt existing method standards. Engineered neutral charge products such as NeutrAvidin and HookDin now compete in the same performance space, which means native avidin is pressured from above by streptavidin and from within the same broader product family by modified avidin variants.Other drivers and restraints analyzed in the detailed report include:
- Expansion of Bioconjugation and Targeted Drug Delivery Workflows
- Increased Use in Immunohistochemistry, Flow Cytometry, and Cell Sorting
- Tight Purity, Endotoxin, and Batch Consistency Requirements
Segment Analysis
Streptavidin held 52.32% of the avidin market share by type in 2025, and that lead reflected its entrenched role in immunoassays, flow cytometry, and biosensor formats where lower nonspecific background remains a decisive buying factor. Native avidin kept a meaningful place in academic and industrial workflows because it stayed widely available, highly soluble in aqueous systems, and cost-effective for ELISA development and affinity purification tasks that can tolerate somewhat higher background. The 2024 and 2025 HPAI cycle in North American poultry exposed the supply vulnerability of egg-derived proteins and encouraged procurement teams to qualify recombinant backups within their vendor panels.Recombinant avidin is projected to grow at 7.53% CAGR from 2026 to 2031, the fastest rate among type segments in the avidin industry, because engineering flexibility and supply independence are becoming more valuable in high-sensitivity use cases. HookDin illustrates the appeal of this direction, since the company states that the format provides 3 times the biotin binding capacity of monomeric streptavidin on nitrocellulose membranes and cuts background noise by 75%.
Research grade avidin accounted for 60.34% of the avidin market in 2025, which reflected the large volume consumed in academic laboratories and industrial research workflows where cost and availability remained more important than very tight release specifications. That segment continued to benefit from routine use in protein purification, ELISA development, cell labeling, and general molecular biology work.
Diagnostic grade avidin is expected to expand at 7.82% CAGR between 2026 and 2031, the fastest pace among grade segments in the avidin market, because more commercial diagnostic demand is moving under formal quality expectations. A key part of that growth comes from a reclassification pattern in which some Asia Pacific manufacturers that have used research grade material for kit production will face stronger compliance pressure as local frameworks move closer to ISO 13485 aligned standards.
Complete Report Scope:
- By Type
- Native Avidin
- Recombinant Avidin
- Streptavidin
- By Grade
- Research Grade Avidin
- Pharmaceutical Grade Avidin
- Diagnostic Grade Avidin
- By Application
- Diagnostics
- Therapeutics
- Research and Development
- Biotechnology
- By Form
- Liquid Avidin
- Powdered Avidin
- Lyophilized Avidin
- By End User
- Biotechnology and Pharmaceutical Companies
- Research Institutions
- Diagnostic Laboratories
- Others (Contract Research Organizations (CROs), Academic Institutes)
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 42.63% of the avidin market share in 2025, making it the largest regional contributor, and the region’s position rests on the high concentration of IVD developers, bioconjugation CDMOs, and life science reagent distributors in the United States. The U.S. base supports demand across research, pharmaceutical, and diagnostic grades because avidin is used in protein purification, immunoassay development, and quality control work for antibody drug conjugate programs.Europe remained the second largest regional market in the avidin market, with Germany, the United Kingdom, and France acting as the main contributors across research, diagnostic, and pharmaceutical grades. Germany benefits from strong pharmaceutical and diagnostic manufacturing, the United Kingdom contributes through a well developed biotechnology base, and France adds stable academic demand.
Asia Pacific is projected to expand at 7.89% CAGR from 2026 to 2031, the fastest regional pace in the avidin market size, because the region combines China’s large IVD manufacturing base, India’s healthcare buildout, Japan’s advanced research environment, and South Korea’s mature diagnostics ecosystem. China remains the largest regional contributor because high volume ELISA and lateral flow production requires steady procurement of avidin related inputs across multiple kit categories.
List of Companies Covered in this Report:
- Abcam
- Avantor
- Avidity Biosciences, Inc.
- BioLegend, Inc.
- Bio-Rad Laboratories
- BioVectra Inc.
- Cell Signaling Technology
- Jackson ImmunoResearch Laboratories, Inc.
- Merck
- MP Biomedicals, LLC
- New England Biolabs
- Promega
- Rockland Immunochemicals
- SouthernBiotech
- Takara Bio
- Thermo Fisher Scientific
- Vector Laboratories, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abcam plc
- Avantor, Inc.
- Avidity Biosciences, Inc.
- BioLegend, Inc.
- Bio-Rad Laboratories, Inc.
- BioVectra Inc.
- Cell Signaling Technology, Inc.
- Jackson ImmunoResearch Laboratories, Inc.
- Merck KGaA
- MP Biomedicals, LLC
- New England Biolabs, Inc.
- Promega Corporation
- Rockland Immunochemicals, Inc.
- SouthernBiotech
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- Vector Laboratories, Inc.
